Government's tougher stance on health insurance embarrasses multinationals

A number of multinational drug manufacturers have been perplexed by the Korean government's tighter process of screening new drugs for the positive list to restrict their newly-invented drugs into Korea, thus discouraging them from developing new drugs.

Multinational companies argued that their newly-invented and original drugs, which have already been undervalued in Korea, will be dealt a s...